Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients

Por von Richter, Oliver, Massimini, Giorgio, Scheible, Holger, Udvaros, Istvan, Johne, Andreas
Publicado no Br J Clin Pharmacol (2016)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

Por Lebbé, Celeste, Dutriaux, Caroline, Lesimple, Thierry, Kruit, Willem, Kerger, Joseph, Thomas, Luc, Guillot, Bernard, de Braud, Filippo, Garbe, Claus, Grob, Jean-Jacques, Loquai, Carmen, Ferraresi, Virginia, Robert, Caroline, Vasey, Paul, Conry, Robert, Isaacs, Richard, Espinosa, Enrique, Schueler, Armin, Massimini, Giorgio, Dréno, Brigitte
Publicado no Cancers (Basel) (2020)